Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • بيانات النشر:
      Frontiers Media SA
    • الموضوع:
      2021
    • Collection:
      Max-Delbrueck-Center for Molecular Medicine, Berlin: MDC Repository
    • نبذة مختصرة :
      Chimeric antigen receptor (CAR) T cell performance against solid tumors in mouse models and clinical trials is often less effective than predicted by CAR construct selection in two-dimensional (2D) cocultures. Three-dimensional (3D) solid tumor architecture is likely to be crucial for CAR T cell efficacy. We used a three-dimensional (3D) bioprinting approach for large-scale generation of highly reproducible 3D human tumor models for the test case, neuroblastoma, and compared these to 2D cocultures for evaluation of CAR T cells targeting the L1 cell adhesion molecule, L1CAM. CAR T cells infiltrated the model, and both CAR T and tumor cells were viable for long-term experiments and could be isolated as single-cell suspensions for whole-cell assays quantifying CAR T cell activation, effector function and tumor cell cytotoxicity. L1CAM-specific CAR T cell activation by neuroblastoma cells was stronger in the 3D model than in 2D cocultures, but neuroblastoma cell lysis was lower. The bioprinted 3D neuroblastoma model is highly reproducible and allows detection and quantification of CAR T cell tumor infiltration, representing a superior in vitro analysis tool for preclinical CAR T cell characterization likely to better select CAR T cells for in vivo performance than 2D cocultures.
    • File Description:
      application/pdf
    • Relation:
      http://edoc.mdc-berlin.de/20480/1/20480oa.pdf; http://edoc.mdc-berlin.de/20480/2/20480suppl.pdf; A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization. Grunewald, L. and Lam, T. and Andersch, L. and Klaus, A. and Schwiebert, S. and Winkler, A. and Gauert, A. and Heeren-Hagemann, A.I. and Astrahantseff, K. and Klironomos, F. and Thomas, A. and Deubzer, H.E. and Henssen, A.G. and Eggert, A. and Schulte, J.H. and Anders, K. and Kloke, L. and Künkele, A. Frontiers in Immunology 12 : 689697. 29 June 2021
    • الرقم المعرف:
      10.3389/fimmu.2021.689697
    • الدخول الالكتروني :
      http://edoc.mdc-berlin.de/20480/
      https://edoc.mdc-berlin.de/20480/
      http://edoc.mdc-berlin.de/20480/1/20480oa.pdf
      http://edoc.mdc-berlin.de/20480/2/20480suppl.pdf
      https://doi.org/10.3389/fimmu.2021.689697
    • Rights:
      cc_by_4
    • الرقم المعرف:
      edsbas.D131C1D2